FIG 8.

Administration of recombinant IL-10 and IL-27 provide separate and partial protection from bone marrow failure in IFrag^−/− mice. (A) Total bone marrow cell numbers of groups of IFrag^−/− mice on day 10 postinfection that received combined treatment with recombinant IL-10 and IL-27 or received IL-10 or IL-27 alone or were left untreated. All cytokines were administered subcutaneously at a concentration of 400 ng/day for IL-10 and 250 ng/day for IL-27. (B to E) In two separate experiments, individual treatment with either IL-27 (B and C) and IL-10 (D and E) were continued throughout day 16 postinfection, and total bone marrow cell numbers were compared to untreated but infected mice (B and D) and hematopoietic progenitor activity was evaluated in colony assays (C and E). For statistical analysis, all comparisons were made to untreated mice and either a one-way ANOVA followed by a Tukey posthoc test or a Student's t test for pairwise comparisons was performed. Values that are significantly different are indicated as follows: *, P < 0.05.